Cardioprotective Effects of Pioglitazone in Type 2 Diabetes.
Tripathy, Devjit Solis-Herrera, Carolina
Tripathy, Devjit
Solis-Herrera, Carolina
Citations
Altmetric:
Affiliation
University of Texas Health Science Center; Foundation for Advancement of Veteran's Health and Research; Sandwell and West Birmingham NHS Trust
Other Contributors
Publication date
2021-08-18
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
Citation
Tripathy D, Solis-Herrera C, Ryder REJ. Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. Diabetes Spectr. 2021 Aug;34(3):243-247.
Type
Article